ArticleDrugs - real world outcomes2026
The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveLenvatinib is a multi-kinase inhibitor approved as a first-line therapy for advanced hepatocellular carcinoma. In India and other low- and middle-income countries, immune checkpoint inhibitor-based regimens are not universally accessible, and real-world data on lenvatinib are limited. We evaluated the effectiveness, safety, and predictors of outcomes of first-line lenvatinib in Indian patients with advanced hepatocellular carcinoma.
methodsThis prospective observational cohort included consecutive patients with advanced hepatocellular carcinoma treated with first-line lenvatinib at the Regional Cancer Centre, Kerala, India, between March 2021 and May 2024. Lenvatinib was started at 8 or 12 mg once daily based on weight. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Cox regression analysis identified independent predictors of outcomes. Toxicities were graded using Common Terminology Criteria for Adverse Events Version 5.0.
resultsA total of 112 patients were enrolled; median age was 62 years, and 88% were male. The predominant etiologies were non-viral (83%), mainly non-alcoholic steatohepatitis and alcohol-related liver disease. Most patients (79 %) had Barcelona Clinic Liver Cancer stage C disease, with nearly half showing macroscopic portal vein invasion. At a median follow-up of 30.8 months, median overall survival was 13.3 months (95% confidence interval [CI] 10.6-16.6) and median progression-free survival was 8.1 months (95% CI 6.5-9.8). Multivariate analysis showed improved overall survival with non-viral etiology (hazard ratio [HR] 0.49, 95% CI 0.28-0.86, p = 0.014), radiological response (HR 0.40, 95% CI 0.22-0.71, p = 0.002), and subsequent therapy (HR 0.36, 95% CI 0.22-0.60, p < 0.001), whereas portal vein invasion predicted worse overall survival (HR 1.67, 95% CI 1.06-2.61, p = 0.026). Grade ≥3 toxicities occurred in 38% of patients, mainly dermatologic, and no treatment-related deaths occurred.
conclusionsLenvatinib demonstrated favorable survival outcomes and manageable toxicity in advanced hepatocellular carcinoma in our cohort, with superior effectiveness in non-viral disease. Given some evidence suggesting that immune checkpoint inhibitors may be less effective in non-viral hepatocellular carcinoma, along with the high costs and lack of accessibility, lenvatinib could still be a viable first-line option for non-viral hepatocellular carcinoma in resource-constrained settings. This is even more relevant with the rising trend of non-viral related hepatocellular carcinoma in low- and middle-income countries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.